News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

3 Lessons From GlaxoSmithKline (GSK)'s Purchase of Human Genome Sciences, Inc. (HGSI)



7/17/2012 8:10:12 AM

After a tedious game of playing hard to get, Human Genome Sciences has finally fallen into the arms of partner GlaxoSmithKline, which will pay $14.25 a share or $3 billion, including cash and debt, $1.25 more per share and $400 million more in total than GSK’s offered back in April. In this long and troubled courtship, there are morals for the use of genetic data to discover drugs, a strategy which remains one of the most likely ways to improve the lackluster success rates of pharmaceutical research labs, and of the mechanics of how companies partner with and buy out one another.

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES